drugset / Trial / NCT07078929
Clinical Trial of CMD63 Chimeric Antigen Receptor T-cell (CAR T-cell) in Children With Acute Lymphoblastic Leukemia (ALL)
Phase 1
Recruiting
16 enrolled
Chulalongkorn University
King Chulalongkorn Memorial Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
A Phase 1 clinical trial to evaluate the safety and early efficacy of Chimeric Antigen Receptor T-cell (CAR T-cell) with IL-7Rα signaling targeting CD19 in children with relapsed and refractory B-cell Acute Lymphoblastic Leukemia (ALL) after complete standard treatments.
Timeline
- Start
- 2026-01-01
- Primary completion
- 2026-09-01
- Completion
- 2028-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD19-IL7Ra CAR-T cells | Cell therapy | 0.5 cells/kg | Other |
| Subject | CD19-IL7Ra CAR-T cells | Cell therapy | 1 cells/kg | Other |